BAKER BROS. ADVISORS LP Q2 2022 Filing
Filed August 15, 2022
Portfolio Value
$17.6B
Holdings
117
Report Date
Q2 2022
Filing Type
13F-HR
All Holdings (117 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 101 | ATYRaTyr Pharma, Inc. | 374,395 | $1.1B | 6.01% | |
| 102 | —Genetron Holdings Limited | 455,306 | $774.0M | 4.39% | |
| 103 | NGMUSDNGM Biopharmaceuticals, Inc. | 55,294 | $709.0M | 4.02% | |
| 104 | CABACabaletta Bio, Inc. | 662,063 | $702.0M | 3.98% | |
| 105 | LPTXEURLeap Therapeutics, Inc. | 559,705 | $644.0M | 3.65% | |
| 106 | FHTXFoghorn Therapeutics Inc. | 45,027 | $612.0M | 3.47% | |
| 107 | BNRBurning Rock Biotech Limited | 209,131 | $609.0M | 3.45% | |
| 108 | TARAProtara Therapeutics, Inc. | 199,671 | $585.0M | 3.32% | |
| 109 | KZRKezar Life Sciences, Inc. | 61,946 | $512.0M | 2.90% | |
| 110 | INZYInozyme Pharma, Inc. | 106,999 | $510.0M | 2.89% | |
| 111 | SERASera Prognostics, Inc. | 201,562 | $331.0M | 1.88% | |
| 112 | —Vincerx Pharma, Inc. | 241,379 | $319.0M | 1.81% | |
| 113 | —Bellicum Pharmaceuticals, Inc. | 249,123 | $296.0M | 1.68% | |
| 114 | PASGPassage Bio, Inc. | 117,161 | $276.0M | 1.57% | |
| 115 | SRZNWSurrozen, Inc. | 833,333 | $159.0M | 0.90% | |
| 116 | —LogicBio Therapeutics, Inc. | 451,478 | $158.0M | 0.90% | |
| 117 | —NexImmune, Inc. | 20,000 | $32.0M | 0.18% |
PreviousPage 2 of 2